Black Box and Nokia Team Up to Create OnGo Private Wireless/CBRS Network for Industry 4.0
Black Box, a leading global solutions integrator, announced today that it has joined with industry wireless communications innovator Nokia to provide the most complete, next-generation OnGo® private wireless/CBRS network for Industry 4.0. The partnership allows Black Box to drive innovation in connectivity and the adoption of private networks, giving the industrial manufacturing market superior options for wireless networking. Black Box explains that OnGo® — an even-licensed, low-band wireless spectrum that gives manufacturers access to private wireless connectivity at a fraction of the cost associated with LTE — mirrors the simplicity of Wi-Fi while providing secure, cost-effective LTE coverage for enterprise wireless traffic and IoT applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211103005142/en/
“Nokia welcomes Black Box to our Global Partner Program to help meet growing demand for private 4G/5G campus networks,” said Vikas Trehan, vice president, channels and alliances for Nokia. “Black Box’s intimate knowledge and trusted relationships within these enterprise campus networks, combined with world-class products and services from Nokia, will help realize the Industry 4.0 vision.”
“Private wireless and emerging private 5G networks are poised to redefine the corporate wireless networking space. Large campuses and sites like airports and large logistics and distribution hubs are pushing current WLAN standards to their technological limits,” said Bill Holman, vice president and general manager of 5G technologies at Black Box. “Thanks to our partnership with Nokia, sites like those can now break free from the limitations of WLAN and get exactly the wireless connectivity they need.”
Black Box designs, builds, and manages a full range of wireless technologies to support connected enterprise, delivering digital workplace connectivity across multiple industries. Leading manufacturers turn to Black Box to help incorporate OnGo® and 5G into their existing and future wireless networks. With Nokia Digital Automation Cloud (DAC) end-to-end private wireless, Black Box helps clients realize the full potential of Industry 4.0.
Further information about Black Box and the company’s global solutions integration services offerings is available at www.blackbox.com.
About Nokia
As a trusted partner for critical networks, we are committed to innovation and technology leadership across mobile, fixed and cloud networks with intellectual property and long-term research led by the award-winning Nokia Bell Labs. Nokia Digital Automation Cloud is a high-performance, LTE/5G end-to-end private wireless networking and edge computing platform. Delivering secure, plug and play, reliable wireless connectivity, Nokia DAC enables industrial use-cases leveraging real-time data for smart manufacturing, predictive maintenance, remote operations and Industrial Internet of Things (IoT) opportunities.
About Black Box
Black Box® is a trusted IT solutions provider delivering cutting-edge technology solutions and world-class consulting services to businesses on every continent. The breadth of our global reach and depth of expertise accelerate customer success by bringing people, ideas, and technology together to solve real-world business problems. Our IT infrastructure solutions, services, and products enable secure, flawless connectivity and meaningful collaboration across town or around the globe.
Black Box is a wholly owned subsidiary of AGC Networks. To learn more, visit the Black Box website at www.blackbox.com. Follow the company on Twitter @BlackBox_ns. Black Box® and the Double Diamond logo are registered trademarks of BB Technologies Inc.
All other trademarks referenced herein are the property of their respective owners.
PR Link:www.wallstcom.com/BlackBox/211103-Black_Box-Nokia_Partnership.docx
Photo: www.wallstcom.com/BlackBox/BlackBox-Nokia_OnGo-Private_Wireless_Network.jpg
Black Box and Nokia Team Up to Create OnGo® Private Wireless/CBRS Network for Industry 4.0
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005142/en/
Contact information
Black Box:
Cristine Kimbrel
Sr. Product Manager | 5G & OnGo
+1.724.873.7044
cristine.kimbrel@BlackBox.com
Nokia:
Evan Forrest
Global Industrial Partner Manager for Nokia
+1.925.413.0015
evan.forrest@nokia.com
About Business Wire
Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new